Constipation - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 107 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Constipation - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Constipation - Pipeline Review, H1 2015', provides an overview of the Constipation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Constipation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Constipation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Constipation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Constipation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Constipation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Constipation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Constipation Overview 8
Therapeutics Development 9
Pipeline Products for Constipation - Overview 9
Pipeline Products for Constipation - Comparative Analysis 10
Constipation - Therapeutics under Development by Companies 11
Constipation - Therapeutics under Investigation by Universities/Institutes 13
Constipation - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Constipation - Products under Development by Companies 18
Constipation - Products under Investigation by Universities/Institutes 19
Constipation - Companies Involved in Therapeutics Development 20
AlbireoPharma 20
Astellas Pharma Inc. 21
AstraZeneca PLC 22
Beech Tree Labs, Inc. 23
Braintree Laboratories, Inc. 24
Daiichi Sankyo Company, Limited 25
Dong-A Socio Group 26
Ironwood Pharmaceuticals, Inc. 27
Kissei Pharmaceutical Co., Ltd. 28
Lipid Pharmaceuticals ehf. 29
Rhythm Pharmaceuticals 30
Sanwa Kagaku Kenkyusho Co., Ltd. 31
Shire Plc 32
SK Biopharmaceuticals Co., Ltd. 33
Sucampo Pharmaceuticals, Inc. 34
Sumitomo Dainippon Pharma Co., Ltd. 35
Synergy Pharmaceuticals, Inc. 36
Teva Pharmaceutical Industries Limited 37
Constipation - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
5-BOIP - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ASP-7663 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
BLI-801 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
DA-6886 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
DS-3801 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
DSP-6952 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
elobixibat - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
KWA-0711 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
linaclotide - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
LP-101 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
lubiprostone - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MDT-006 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
plecanatide - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
prucalopride succinate - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
relamorelin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
SK-1202 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecule for Chronic Constipation - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
tenapanor hydrochloride - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Transilon - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
YKP-10811 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Constipation - Recent Pipeline Updates 76
Constipation - Dormant Projects 97
Constipation - Product Development Milestones 98
Featured News & Press Releases 98
Nov 20, 2014: Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan 98
Nov 12, 2014: Sucampo Files Patent Infringement Lawsuit Against Dr. Reddy's 98
Nov 04, 2014: Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation 99
Oct 24, 2014: Rhythm Presents Positive Phase 2 Study Results for Relamorelin for Chronic Constipation 99
Oct 13, 2014: Clinical Data for AMITIZA Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting 101
Oct 09, 2014: Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA 102
Sep 18, 2014: Synergy Pharmaceuticals Reaches Halfway Mark for Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation 103
Aug 21, 2014: Sucampo Announces New Exclusive Global Manufacturing and Supply Agreement for Lubiprostone 103
Jul 14, 2014: Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation 104
May 06, 2014: Rhythm Presents Positive GI Motility Results for Relamorelin (RM-131) in Phase 2 Chronic Constipation Study 104
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 107
Disclaimer 107

List of Tables
Number of Products under Development for Constipation, H1 2015 9
Number of Products under Development for Constipation - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Comparative Analysis by Unknown Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Investigation by Universities/Institutes, H1 2015 19
Constipation - Pipeline by AlbireoPharma, H1 2015 20
Constipation - Pipeline by Astellas Pharma Inc., H1 2015 21
Constipation - Pipeline by AstraZeneca PLC, H1 2015 22
Constipation - Pipeline by Beech Tree Labs, Inc., H1 2015 23
Constipation - Pipeline by Braintree Laboratories, Inc., H1 2015 24
Constipation - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 25
Constipation - Pipeline by Dong-A Socio Group, H1 2015 26
Constipation - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 27
Constipation - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 28
Constipation - Pipeline by Lipid Pharmaceuticals ehf., H1 2015 29
Constipation - Pipeline by Rhythm Pharmaceuticals, H1 2015 30
Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2015 31
Constipation - Pipeline by Shire Plc, H1 2015 32
Constipation - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 33
Constipation - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2015 34
Constipation - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 35
Constipation - Pipeline by Synergy Pharmaceuticals, Inc., H1 2015 36
Constipation - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 37
Assessment by Monotherapy Products, H1 2015 38
Number of Products by Stage and Target, H1 2015 40
Number of Products by Stage and Mechanism of Action, H1 2015 42
Number of Products by Stage and Route of Administration, H1 2015 44
Number of Products by Stage and Molecule Type, H1 2015 46
Constipation Therapeutics - Recent Pipeline Updates, H1 2015 76
Constipation - Dormant Projects, H1 2015 97